Compare MakeMyTrip Ltd (MMYT) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MakeMyTrip Ltd vs BIO-TECHNE Corp — how do they compare? MakeMyTrip Ltd trades at $43.71 (market cap $4.09B), while BIO-TECHNE Corp trades at $72.46 (market cap $11.36B). The key difference: BIO-TECHNE Corp is far larger — about 2.8× MakeMyTrip Ltd's market cap, and BIO-TECHNE Corp pays a 0.44% dividend while MakeMyTrip Ltd pays none. Which is the better fit depends on your goals — on Pluang, investors hold MakeMyTrip Ltd for 12 Days and BIO-TECHNE Corp for 63 Days on average.
| MMYT | TECH | |
|---|---|---|
Market Cap | $4.09B | $11.36B |
Volume | 1,828,010 | 5,390,331 |
Sector | Consumer Cyclical | Health |
52-Week High | $94.43 | $72.61 |
52-Week Low | $36.30 | $43.31 |
Typical Hold Time | 12 Days | 63 Days |
Enterprise Value | $4.75B | $11.39B |
Dividend Yield | — | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MakeMyTrip (MMYT) trades at $43.41 with minimal daily movement (+0.09%). The stock shows mixed technical signals with a bearish overall trend but oversold RSI readings. Fundamentally, the company maintains strong revenue growth (2025: $978M, 2026: $1.1B) and a robust gross margin of 73.45%, though net margins have compressed from 9.72% to 3.22%. Recent earnings show volatility with one beat and two misses in the last four quarters.
Wall Street maintains strong bullish sentiment with a $77 consensus price target (72.7% buy ratings), representing 77% upside potential. Key risks include declining profitability margins, significant debt increase forecasted for 2026, and competitive pressures in the travel sector. The planned Indian subsidiary IPO could unlock value but execution remains critical.
TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal from moving averages. The company reported mixed quarterly earnings, beating in Q4 2025 and Q2 2026 but missing in Q1 2026. Revenue for 2025 was $1.22B, with a net income margin of 14.97%. Valuation ratios are elevated, with a P/E of 62.46 and P/S of 9.36. A significant development is the shareholder-approved acquisition by Merck KGaA at $73.00 per share, pending completion.
The outlook is heavily influenced by the pending acquisition, offering a near-term price ceiling. Fundamentals show solid profitability but high valuation multiples. Risks include acquisition deal completion uncertainty and integration challenges. Analyst sentiment is mixed with no sell ratings, but the consensus price target of $65.78 suggests limited upside from current levels, making the stock a hold pending acquisition closure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About MakeMyTrip Ltd
MakeMyTrip Ltd. is a leading online travel company in India, providing a comprehensive range of travel services and products, including air tickets, hotels, holiday packages, rail tickets, and bus tickets. The company operates its primary websites and mobile apps under the brands MakeMyTrip, Goibibo, and RedBus. MMYT serves as a key intermediary in India's fragmented travel market, leveraging its platform to offer convenience and competitive pricing to consumers and businesses.
Read more on MMYT →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
